US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Gensight Biologics SA

0.1901

0.0000

Volume:- -

Turnover:- -

Market Cap:41.92M

PE:-1.27

High:0.1901

Open:0.1901

Low:0.1901

Close:0.1901

52wk High:0.2400

52wk Low:0.1901

Shares:220.49M

Float Shares:43.56M

Volume Ratio:0.00

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.1498

EPS(LYR):-0.1514

ROE:-7781.69%

ROA:-85.07%

PB:-1.10

PE(LYR):-1.26

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Gensight Biologics SA

Exchange:

EXPERT

Establishment Date:

2012

Employees:

13

Office Location:

74, rue du Faubourg Saint-Antoine,Paris,Ile-de-France,France

Website:

- -

Zip Code:

75012

Phone:

33 1 76 21 72 20

Fax:

- -

Introduction:

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. The company was incorporated in 2012 and is headquartered in Paris, France.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/GSGTF/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GSGTF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSGTF\",,,,,undefined,":{"symbol":"GSGTF","market":"US","secType":"STK","nameCN":"Gensight Biologics SA","latestPrice":0.1901,"timestamp":1770411600000,"preClose":0.1901,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":43563685,"shares":220493679,"eps":-0.149825,"marketStatus":"Not Yet Opened","change":0,"latestTime":"02-06 16:00:00 EST Delay","open":0.1901,"high":0.1901,"low":0.1901,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.149825,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"EXPERT","adjPreClose":0.1901,"volumeRatio":0.004641232698483526},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSGTF\",,,,,undefined,":{"symbol":"GSGTF","floatShares":43563685,"roa":"-85.07%","roe":"-7781.69%","lyrEps":-0.151378,"volumeRatio":0.004641232698483526,"shares":220493679,"dividePrice":0,"high":0.1901,"amplitude":0,"preClose":0.1901,"low":0.1901,"week52Low":0.1901,"pbRate":"-1.10","psRate":"37.40","week52High":0.24,"institutionHeld":0,"latestPrice":0.1901,"eps":-0.149825,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.149825,"open":0.1901,"prevYearClose":0.1901,"prevWeekClose":0.1901,"prevMonthClose":0.1901,"prevQuarterClose":0.1901,"fiveDayClose":0.1901,"twentyDayClose":0.1901,"sixtyDayClose":0.1901},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GSGTF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2022-10-28","symbol":"GSGTF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1666929600000,"reportTimeType":"","actualEps":null},{"date":"2022-04-08","symbol":"GSGTF","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1649404800000,"name":null,"time":"","dateTimestamp":1649390400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GSGTF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GSGTF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.3333,"hold":0.6667,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.6667,"analysts":3,"updateTime":1752037200000},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":235063288,"yearFounded":2012,"employeeNum":13,"address":"74, rue du Faubourg Saint-Antoine,Paris,Ile-de-France,France","zipCode":"75012","officePhone":"33 1 76 21 72 20"},"stockCompanyDetail":{"stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.1944},{"period":"3month","weight":-0.1944},{"period":"6month","weight":-0.413},{"period":"1year","weight":-0.5452},{"period":"ytd","weight":-0.2402}],"description":"GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. The company was incorporated in 2012 and is headquartered in Paris, France.","exchange":"EXPERT","name":"Gensight Biologics SA","nameEN":"Gensight Biologics SA"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"GSGTF\",market:\"US\",,,undefined,":null}}